Skip to main content

mepolizumab (Nucala®)


Status: One Wales interim decision

It is the view of the Interim Pathways Commissioning Group (IPCG) that mepolizumab (Nucala®) should continue to not be supported within NHS Wales for the treatment of chronic eosinophilic pneumonia.

Individual Patient Funding Request (IPFR) consideration remains appropriate for those patients who are likely to obtain significantly more clinical benefit from the intervention than would normally be expected at a reasonable value for money.

This advice will be reviewed after 12 months or earlier if new evidence becomes available.

 One Wales Interim Decision with evidence review. Mepolizumab for CEP. OW15. 2022.pdf (PDF, 78Kb)

Medicine details

Medicine name mepolizumab (Nucala®)
Formulation Solution for injection
Reference number OW15

Treatment of chronic eosinophilic pneumonia

Company GlaxoSmithKline
BNF chapter Respiratory system
Submission type One Wales
Status One Wales interim decision
Date of issue 09/01/2020
Date of last review 17/05/2022
Follow AWTTC: